Convexia

AI-powered drug discovery 10x faster

Convexia is an AI-driven biotech platform focused on accelerating pharmaceutical drug discovery and development. It uses modular agents and over 50 computational models to identify and evaluate drug candidates, claiming to operate 10x faster and 20x leaner than incumbents.

Shareable draft

Check out Convexia on @MedStartr Today Convexia is an AI-driven biotech platform focused on accelerating pharmaceutical drug discovery and development. It uses modular agents and over 50 computational models to identify and evaluate drug candidates, claiming to operate 10x faster and 20x leaner than incumbents. #MentalBehavioralHealth #DrugDiscoveryDevelopment #MedMo #MedStartrVentures

https://www.medstartr.ai/s/arNbK-AgFrg

Get Involved in Convexia

How We Help

Problem Statement

Convexia addresses the limitations of traditional, manual diligence processes in drug discovery, which often lead to promising drug candidates being overlooked, shelved, or abandoned due to their slow and costly nature.

Core Technology

Convexia employs an AI-driven biotech platform featuring modular agents and over 50 custom-tuned computational models. These models evaluate drug candidates across domains like binding, ADME, toxicity, and immunogenicity, accelerating discovery and development.

Key Differentiators

Operates 10x faster than incumbents; Operates 20x leaner than incumbents; Operates without wet lab infrastructure, partnering with Contract Research Organizations (CROs); Includes human review layer with domain experts and Key Opinion Leaders (KOLs) validating AI findings

Clinical Focus

Drug Discovery; Drug Development; Clinical Trial Simulation

Company Info

Business Model: B2B SaaS
Founded: 2025
Total Funding: Only accessible to MedStartr community members. Join now
Only accessible to MedStartr community members.
Join now

Disease Areas

Mental Health

Technologies

Computational BiologyMachine LearningAgent-Based SystemsAI & Machine Learning

Clinical & IP

🔬

Clinical Validation

In-silico computational biology models (ESM-3, AlphaFold), IND-enabling studies via CRO partnerships, clinical trial simulations, Phase 1 pathway planning, expert review by domain scientists

MedStartr Engagement Score

The MedStartr Index is a reflection of how the crowds that come to MedStartr everyday to find healthcare innovations reacted. Calculated by our AI agent Fyggy based on algorithms we have been building since 2012 and over 100 different factors, the math is proprietary and complex. Suffice to say, it has been found to be highly correlative with early stage company growth. What you see here is the public version. To learn more or to get deeper access to our predictive data on startup success for your fund or company, click here.

Comments

Comments from new members are shown once the company's team has approved them. Please follow the community rules.

Be the first to comment.

What do you think of Convexia?

A HUGE part of what early stage companies, and even late stage ones, need and get on MedStartr is honest feedback from actual patients, clinicians, hospital leaders and industry insiders. It is very easy to get tunnel vision as a founder. Please tell the team that runs this company what you think.

Clinical Benefit Potential

The potential for a project to have a large and significant impact on medical care, treatment, or prevention.

Feasibility

The likelihood that this will provide benefit for patients / care givers and that the founders can execute on their vision and plan.

Innovativeness

The distinguishing features, concept, or technology that differentiates the entry compared to others that already exist and are in widespread use.

Fundability

The reviewers' beliefs that the idea is fundable or can make it to sustainability without outside investment.

Scalability

Some great ideas are destined to failure because they are too complex or too expensive. The reviewer should consider the likelihood that a project as explained, or perhaps with some tweaks, could possibly become a worldwide solution within a reasonable time frame.

Presentation Quality

How well the team presented the idea.

Submit anonymously — my name won't be shown to the team or on this profile

Your scores and comments are shown with your review on this company's profile.